GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Galderma to buy US firm ZO Skin Health for $1.5 billion - Finance news and analysis from Global Banking & Finance Review
Finance

Galderma to buy US firm ZO Skin Health for $1.5 billion

Published by Global Banking & Finance Review

Posted on October 14, 2026

2 min read

· Last updated: October 14, 2026

Add as preferred source on Google

Galderma Announces $1.5 Billion Acquisition of ZO Skin Health to Expand Skincare

Galderma's Strategic Acquisition of ZO Skin Health

ZURICH, Oct 14 (Reuters) - Swiss skincare firm Galderma said on Wednesday it had agreed to acquire US-based company ZO Skin Health for an enterprise value of $1.5 billion, confirming a report published by Reuters earlier in the day.

Details of the Acquisition

  • The acquisition brings together two complementary, science-backed skincare brands, ZO Skin Health and Galderma's Alastin

Expansion of Dermatological Skincare Offering

  • Galderma said the deal would expand its dermatological skincare offering in fast-growing, physician-dispensed skincare and support ZO Skin Health's next phase of growth.
Transaction Timeline and Financial Impact
  • The transaction is expected to close in the fourth quarter of 2026 or early 2027, subject to regulatory approvals.
  • The Swiss company said the acquisition of 100% of ZO Skin Health is expected to be neutral to core earnings per share in the first full year after the transaction closes.

About ZO Skin Health

  • Irvine, California-based ZO Skin Health has operated in professional skincare for more than 20 years.
  • ZO Skin Health logged net sales of around $330 million in the twelve months leading up to June 2026.

(Writing by Dave GrahamEditing by Linda Pasquini)

Key Takeaways

  • The all‑cash acquisition of 100 % of ZO Skin Health complements Galderma’s Alastin line and targets the fast‑growing physician‑dispensed skincare segment, expected to close in Q4 2026 or early 2027.
  • ZO Skin Health, founded by Dr Zein Obagi and backed by Blackstone, achieved roughly US$330 million in net sales over the 12 months to June 2026.
  • The acquisition is projected to be neutral to Galderma’s core EPS in the first full year post‑closing and aims to unlock synergies in innovation, commercial expansion and global reach.

References

Frequently Asked Questions

What company is Galderma acquiring?
Galderma is acquiring US-based skincare firm ZO Skin Health.
What is the value of the Galderma-ZO Skin Health deal?
The acquisition is valued at $1.5 billion.
When is the Galderma-ZO Skin Health transaction expected to close?
The transaction is expected to close in the fourth quarter of 2026 or early 2027, subject to regulatory approvals.
How will the deal affect Galderma’s earnings?
The acquisition is expected to be neutral to core earnings per share in the first full year after closing.
What was ZO Skin Health's net sales before the acquisition?
ZO Skin Health logged net sales of around $330 million in the twelve months leading up to June 2026.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category